Scheme S1. Synthesis of the PEG linker whose one side is thioctic acid and the other side is terminated in N-hydroxysucinimide (NHS)-activated carboxylic acid. (DMAP is the catalyst)
. MALDI-TOF-MS data for the intermediate product and the final product indicated in Scheme S1. Figure S2 . The preparation protocol of antibody (Ab)-functionalized AuNPs starting from citrate-stabilized AuNPs. Figure S3 . UV-vis absorption spectra of citrate-AuNPs, PEG-AuNPs, and Ab-AuNPs. The graduate red-shift of the absorption bands indicates the success of the step-by-step functionalization shown in Figure S2 . Table S1 . Comparison of normalized electric-field magnitude and intensity for different sized mono-dispersed AuNPs. Table S2 . Comparison of normalized electric-field magnitude and intensity in the nano-gap for AuNPs oligomers composed of different sized AuNPs. Table S3 . Comparison of AuNP-based immunoassays for various detection targets. Table S4 . The -ΔA 525 values using the proposed AuNP-based colorimetric immunoassay for the clinical samples collected from 6 healthy individuals and 18 patients suffering from cancer. Table S5 . Clinical information of the 6 healthy individuals. 
